Multiple Sclerosis (MS) Latest Advances

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics

Published: June 24, 2026

Cognitive impairment in multiple sclerosis: Where do we stand today?

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 23, 2026

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 23, 2026

Immuno-Proteomic Features Associated to Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 23, 2026

Serum neurofilament light chain in paediatric patients treated with natalizumab for highly active multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 23, 2026

Design, Biological Characterization, and Discovery of the Brain-Penetrant NLRP3 Inhibitor Based on a [1,2,4]Triazolo[1,5-a]pyrimidine Scaffold for the Treatment of Central Nervous System Diseases.

Journal: Journal of medicinal chemistry

Published: June 23, 2026

Exosomes: A new frontier in the treatment of neurological diseases.

Journal: iScience

Published: June 22, 2026

Quantitative determination of longitudinal CNS cholesterol loss during myelin damage and repair.

Journal: bioRxiv : the preprint server for biology

Published: June 22, 2026

Implementing Co-innovation to Develop an Accessible, Web-Based Exercise Program for People with Multiple Sclerosis.

Journal: Archives of rehabilitation research and clinical translation

Published: June 22, 2026

Home-based exoskeleton use to improve quality of life in patients with multiple sclerosis: study protocol of a multicentre, randomised, cross-over trial.

Journal: BMJ open

Published: June 22, 2026

Correction: A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats.

Journal: Inflammation and regeneration

Published: June 21, 2026

Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.

Journal: Journal of medical economics

Published: June 21, 2026

Multiple Sclerosis (MS) Latest Advances

Find the Latest Research About Multiple Sclerosis (MS)

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Cognitive impairment in multiple sclerosis: Where do we stand today?

Cognitive impairment in multiple sclerosis: Where do we stand today?

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Immuno-Proteomic Features Associated to Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Immuno-Proteomic Features Associated to Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Serum neurofilament light chain in paediatric patients treated with natalizumab for highly active multiple sclerosis.

Serum neurofilament light chain in paediatric patients treated with natalizumab for highly active multiple sclerosis.

Design, Biological Characterization, and Discovery of the Brain-Penetrant NLRP3 Inhibitor Based on a [1,2,4]Triazolo[1,5-a]pyrimidine Scaffold for the Treatment of Central Nervous System Diseases.

Design, Biological Characterization, and Discovery of the Brain-Penetrant NLRP3 Inhibitor Based on a [1,2,4]Triazolo[1,5-a]pyrimidine Scaffold for the Treatment of Central Nervous System Diseases.

Exosomes: A new frontier in the treatment of neurological diseases.

Exosomes: A new frontier in the treatment of neurological diseases.

Quantitative determination of longitudinal CNS cholesterol loss during myelin damage and repair.

Quantitative determination of longitudinal CNS cholesterol loss during myelin damage and repair.

Implementing Co-innovation to Develop an Accessible, Web-Based Exercise Program for People with Multiple Sclerosis.

Implementing Co-innovation to Develop an Accessible, Web-Based Exercise Program for People with Multiple Sclerosis.

Home-based exoskeleton use to improve quality of life in patients with multiple sclerosis: study protocol of a multicentre, randomised, cross-over trial.

Home-based exoskeleton use to improve quality of life in patients with multiple sclerosis: study protocol of a multicentre, randomised, cross-over trial.

Correction: A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats.

Correction: A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats.

Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.

Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.